Diagnosis of acromegaly: state of the art

Bibliography

• Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the newcastle region. Clin Endocrinol (Oxf) 1980;12:71-9
   PubMed Web of Science ®Google Scholar
• Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of liege, belgium. J Clin Endocrinol Metab 2006;91:4769-75
   PubMed Web of Science ®Google Scholar
• Rosario PW. Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 2011;14:217-21
   PubMed Web of Science ®Google Scholar
• Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95-102
   PubMed Web of Science ®Google Scholar
• Bengtsson BA, Eden S, Ernest I, et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988;223:327-35
   PubMed Web of Science ®Google Scholar
• Swearingen B, Barker FG II, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419-26
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008;159:89-95
   PubMed Web of Science ®Google Scholar
• Matsuoka LY, Wortsman J, Kupchella CE, et al. Histochemical characterization of the cutaneous involvement of acromegaly. Arch Intern Med 1982;142:1820-3
   PubMed Web of Science ®Google Scholar
• Jadresic A, Banks LM, Child DF, et al. The acromegaly syndrome. relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med 1982;51:189-204
   PubMedGoogle Scholar
• Schneider HJ, Kosilek RP, Gunther M, et al. A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification. J Clin Endocrinol Metab 2011;96:2074-80
   PubMed Web of Science ®Google Scholar
• Miller RE, Learned-Miller EG, Trainer P, et al. Early diagnosis of acromegaly: computers vs clinicians. Clin Endocrinol (Oxf) 2011;75:226-31
   PubMed Web of Science ®Google Scholar
• Attal P, Chanson P. Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab 2010;95:483-95
   PubMed Web of Science ®Google Scholar
• Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 2013;98:1040-50
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: Persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005;90:2731-9
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Sohaib SA, Akker S, et al. The pathology of median neuropathy in acromegaly. Ann Intern Med 2000;133:197-201
   PubMed Web of Science ®Google Scholar
• Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 2005;63:470-6
   PubMed Web of Science ®Google Scholar
• Vitale G, Galderisi M, Pivonello R, et al. Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass. Clin Endocrinol (Oxf) 2004;60:343-9
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Grasso LF, et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol 2011;165:713-21
   PubMed Web of Science ®Google Scholar
• Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 2004;89:5308-13
   PubMed Web of Science ®Google Scholar
• Loeper S, Ezzat S. Acromegaly: re-thinking the cancer risk. Rev Endocr Metab Disord 2008;9:41-58
   PubMed Web of Science ®Google Scholar
• Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355:2558-73
   PubMed Web of Science ®Google Scholar
• Rokkas T, Pistiolas D, Sechopoulos P, et al. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol 2008;14:3484-9
   PubMed Web of Science ®Google Scholar
• Jenkins PJ, Fairclough PD; British Society for Gastroenterology, Association of Coloproctology for Great Britain and Ireland. Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut 2002;51:V13-14
   PubMed Web of Science ®Google Scholar
• dos Santos MC, Nascimento GC, Nascimento AG, et al. Thyroid cancer in patients with acromegaly: a case-control study. Pituitary 2013;16:109-14
   PubMed Web of Science ®Google Scholar
• Gullu BE, Celik O, Gazioglu N, et al. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010;13:242-8
   PubMed Web of Science ®Google Scholar
• Levy MJ, Matharu M, Goadsby PJ. Chronic headache and pituitary tumors. Curr Pain Headache Rep 2008;12:74-8
   PubMed Web of Science ®Google Scholar
• Webb SM, Casanueva F, Wass JA. Oncological complications of excess GH in acromegaly. Pituitary 2002;5:21-5
   PubMedGoogle Scholar
• Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev 2010;31:301-42
   PubMed Web of Science ®Google Scholar
• Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the spanish acromegaly registry (registro espanol de acromegalia, REA). Eur J Endocrinol 2004;151:439-46
   PubMed Web of Science ®Google Scholar
• Kasayama S, Otsuki M, Takagi M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52:549-55
   PubMed Web of Science ®Google Scholar
• Fieffe S, Morange I, Petrossians P, et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the french acromegaly registry. Eur J Endocrinol 2011;164:877-84
   PubMed Web of Science ®Google Scholar
• Ciresi A, Amato MC, Pivonello R, et al. The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 2013;98:E51-9
   PubMed Web of Science ®Google Scholar
• Kamenicky P, Blanchard A, Gauci C, et al. Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria? J Clin Endocrinol Metab 2012;97:2124-33
   PubMed Web of Science ®Google Scholar
• Shah R, Licata A, Oyesiku NM, et al. Acromegaly as a cause of 1,25-dihydroxyvitamin D-dependent hypercalcemia: case reports and review of the literature. Pituitary 2012;15:S17-22
   PubMedGoogle Scholar
• White HD, Ahmad AM, Durham BH, et al. Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab 2006;91:913-19
   PubMed Web of Science ®Google Scholar
• Ueda M, Inaba M, Tahara H, et al. Hypercalcemia in a patient with primary hyperparathyroidism and acromegaly: distinct roles of growth hormone and parathyroid hormone in the development of hypercalcemia. Intern Med 2005;44:307-10
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Lotti T, Jajic I, et al. The clinical spectrum of pachydermoperiostosis (primary hypertrophic osteoarthropathy). Medicine (Baltimore) 1991;70:208-14
   PubMed Web of Science ®Google Scholar
• Kumar KV, Shaikh A, Anwar I, et al. Primary hypothyroidism presenting as pseudoacromegaly. Pituitary 2012;15:S49-52
   PubMedGoogle Scholar
• Ghazi A, Khosla S, Becker K. Acromegaloid facial appearance: case report and literature review. Case Rep Endocrinol 2013;2013:970396
   Google Scholar
• Kumar S, Durrington PN, O'Rahilly S, et al. Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab 1996;81:3465-8
   PubMed Web of Science ®Google Scholar
• Sam AH, Tan T, Meeran K. Insulin-mediated "pseudoacromegaly". Hormones (Athens) 2011;10:156-61
   PubMedGoogle Scholar
• Katznelson L, Atkinson JL, Cook DM, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update: executive summary. Endocr Pract 2011;17:636-46
   PubMed Web of Science ®Google Scholar
• Subbarayan SK, Fleseriu M, Gordon MB, et al. Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone. Endocr Pract 2012;18:817-25
   PubMed Web of Science ®Google Scholar
• Brabant G, von zur Muhlen A, Wuster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003;60:53-60
   PubMed Web of Science ®Google Scholar
• Gleeson HK, Lissett CA, Shalet SM. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J Clin Endocrinol Metab 2005;90:1061-7
   PubMed Web of Science ®Google Scholar
• Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17:328-36
   PubMed Web of Science ®Google Scholar
• Schneider HJ, Saller B, Klotsche J, et al. Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol 2006;15:699-706
   Google Scholar
• Berrigan D, Potischman N, Dodd KW, et al. Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults. Growth Horm IGF Res 2009;19:146-55
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am 2012;41:425-43. vii-viii
   PubMed Web of Science ®Google Scholar
• Frystyk J, Freda P, Clemmons DR. The current status of IGF-I assays–a 2009 update. Growth Horm IGF Res 2010;20:8-18
   PubMed Web of Science ®Google Scholar
• Pokrajac A, Wark G, Ellis AR, et al. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 2007;67:65-70
   PubMed Web of Science ®Google Scholar
• Chen JW, Ledet T, Orskov H, et al. A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab 2003;284:E1149-55
   PubMed Web of Science ®Google Scholar
• Brugts MP, Ranke MB, Hofland LJ, et al. Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. J Clin Endocrinol Metab 2008;93:2539-45
   PubMed Web of Science ®Google Scholar
• Neidert MC, Sze L, Zwimpfer C, et al. Soluble alpha-klotho: a novel serum biomarker for the activity of GH-producing pituitary adenomas. Eur J Endocrinol 2013;168:575-83
   PubMed Web of Science ®Google Scholar
• Sze L, Bernays RL, Zwimpfer C, et al. Excessively high soluble klotho in patients with acromegaly. J Intern Med 2012;272:93-7
   PubMed Web of Science ®Google Scholar
• Biller BM, Vance ML, Kleinberg DL, et al. Clinical and reimbursement issues in growth hormone use in adults. Am J Manag Care 2000;6:S817-27
   PubMed Web of Science ®Google Scholar
• Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 1988;67:69-73
   PubMed Web of Science ®Google Scholar
• Heald A, Kaushal K, Anderson S, et al. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk. Gynecol Endocrinol 2005;20:176-82
   PubMed Web of Science ®Google Scholar
• Arafat AM, Mohlig M, Weickert MO, et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 2008;93:1254-62
   PubMed Web of Science ®Google Scholar
• Iranmanesh A, Lawson D, Veldhuis JD. Distinct metabolic surrogates predict basal and rebound GH secretion after glucose ingestion in men. J Clin Endocrinol Metab 2012;97:2172-9
   PubMed Web of Science ®Google Scholar
• Minuto FM, Resmini E, Boschetti M, et al. Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. Pituitary 2012;15:215-21
   PubMed Web of Science ®Google Scholar
• Grottoli S, Procopio M, Maccario M, et al. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion. J Clin Endocrinol Metab 1997;82:2261-5
   PubMed Web of Science ®Google Scholar
• Chapman IM, Hartman ML, Straume M, et al. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than women. J Clin Endocrinol Metab 1994;78:1312-19
   PubMed Web of Science ®Google Scholar
• Dimaraki EV, Jaffe CA, DeMott-Friberg R, et al. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002;87:3537-42
   PubMed Web of Science ®Google Scholar
• Ribeiro-Oliveira A Jr, Faje AT, Barkan AL. Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol 2011;164:17-22
   PubMed Web of Science ®Google Scholar
• Grottoli S, Razzore P, Gaia D, et al. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. J Endocrinol Invest 2003;26:123-7
   PubMed Web of Science ®Google Scholar
• Freda PU, Post KD, Powell JS, et al. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808-16
   PubMed Web of Science ®Google Scholar
• Westermark K, Alm J, Skottner A, et al. Growth factors and the thyroid: effects of treatment for hyper- and hypothyroidism on serum IGF-I and urinary epidermal growth factor concentrations. Acta Endocrinol (Copenh) 1988;118:415-21
   PubMedGoogle Scholar
• Clemmons DR. IGF-I assays: current assay methodologies and their limitations. Pituitary 2007;10:121-8
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 2011;57:555-9
   PubMed Web of Science ®Google Scholar
• Carmichael JD, Bonert VS, Mirocha JM, et al. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009;94:523-7
   PubMed Web of Science ®Google Scholar
• Machado EO, Taboada GF, Neto LV, et al. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res 2008;18:389-93
   PubMed Web of Science ®Google Scholar
• Brzana JA, Yedinak CG, Delashaw JB, et al. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naive to medical therapy and radiation: What to follow, GH or IGF-1 values? Pituitary 2012;15:562-70
   PubMed Web of Science ®Google Scholar
• Miell JP, Taylor AM, Zini M, et al. Effects of hypothyroidism and hyperthyroidism on insulin-like growth factors (IGFs) and growth hormone- and IGF-binding proteins. J Clin Endocrinol Metab 1993;76:950-5
   PubMed Web of Science ®Google Scholar
• Bianchi A, Giustina A, Cimino V, et al. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 2009;94:2015-22
   PubMed Web of Science ®Google Scholar
• Lansang C, Chitaia N, Simpson NE, et al. Serum IGF-1 in treated acromegaly - how normal is “normal”? Pituitary 2005;8:135-8
   PubMedGoogle Scholar
• Neggers SJ, Biermasz NR, van der Lely AJ. What is active acromegaly and which parameters do we have? Clin Endocrinol (Oxf) 2012;76:609-14
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754-9
   PubMed Web of Science ®Google Scholar
• Miller KK, Wexler T, Fazeli P, et al. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab 2010;95:567-77
   PubMed Web of Science ®Google Scholar
• Lonser RR, Kindzelski BA, Mehta GU, et al. Acromegaly without imaging evidence of pituitary adenoma. J Clin Endocrinol Metab 2010;95:4192-6
   PubMed Web of Science ®Google Scholar
• Stobo DB, Lindsay RS, Connell JM, et al. Initial experience of 3 tesla versus conventional field strength magnetic resonance imaging of small functioning pituitary tumours. Clin Endocrinol (Oxf) 2011;75:673-7
   PubMed Web of Science ®Google Scholar
• Appel JG, Bergsneider M, Vinters H, et al. Acromegaly due to an ectopic pituitary adenoma in the clivus: case report and review of literature. Pituitary 2012;15:S53-6
   PubMedGoogle Scholar
• Heck A, Ringstad G, Fougner SL, et al. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 2012;77:72-8
   PubMed Web of Science ®Google Scholar
• Manara R, Maffei P, Citton V, et al. Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature. J Clin Endocrinol Metab 2011;96:1292-300
   PubMed Web of Science ®Google Scholar
• Oshino S, Nishino A, Suzuki T, et al. Prevalence of cerebral aneurysm in patients with acromegaly. Pituitary 2012;16:195-201
   Web of Science ®Google Scholar
• Pawlikowski M, Kuta J, Fuss-Chmielewska J, et al. ‘Silent' somatotropinoma. Endokrynol Pol 2012;63:88-91
   PubMed Web of Science ®Google Scholar
• Brzana J, Yedinak CG, Gultekin SH, et al. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Larkin S, Reddy R, Karavitaki N, et al. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur J Endocrinol 2013;168:491-9
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2013;98:E66-71
   PubMed Web of Science ®Google Scholar
• Schroeder JL, Spiotta AM, Fleseriu M, et al. Absence of immunostaining for growth hormone in a subset of patients with acromegaly. Pituitary 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Katznelson L. Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab 2010;95:4114-23
   PubMed Web of Science ®Google Scholar
• Krzentowska-Korek A, Golkowski F, Baldys-Waligorska A, et al. Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary 2011;14:157-62
   PubMed Web of Science ®Google Scholar
• Wang M, Mou C, Jiang M, et al. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases. Eur J Endocrinol 2012;166:797-802
   PubMed Web of Science ®Google Scholar
• Takamoto S, Tsuchiya H, Onishi T, et al. Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. J Clin Endocrinol Metab 1985;61:7-11
   PubMed Web of Science ®Google Scholar
• Cheng V, Faiman C, Kennedy L, et al. Pregnancy and acromegaly: a review. Pituitary 2012;15:59-63
   PubMed Web of Science ®Google Scholar
• Herder WW. Familial gigantism. Clinics (Sao Paulo) 2012;67:29-32
   PubMed Web of Science ®Google Scholar
• Lumbroso S, Paris F, Sultan C. European Collaborative Study. Activating gsalpha mutations: analysis of 113 patients with signs of McCune-albright syndrome–a european collaborative study. J Clin Endocrinol Metab 2004;89:2107-13
   PubMed Web of Science ®Google Scholar
• Vortmeyer AO, Glasker S, Mehta GU, et al. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-albright syndrome. J Clin Endocrinol Metab 2012;97:2404-13
   PubMed Web of Science ®Google Scholar
• Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the france-belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002;87:457-65
   PubMed Web of Science ®Google Scholar
• Pack SD, Kirschner LS, Pak E, et al. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (carney complex). J Clin Endocrinol Metab 2000;85:3860-5
   PubMed Web of Science ®Google Scholar
• Pinho LK, Vieira Neto L, Wildemberg LE, et al. Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening. Arq Bras Endocrinol Metabol 2010;54:698-704
   PubMed Web of Science ®Google Scholar
• Chahal HS, Chapple JP, Frohman LA, et al. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab 2010;21:419-27
   PubMed Web of Science ®Google Scholar
• Garby L, Caron P, Claustrat F, et al. Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing hormone (GHRH): a french nationwide series of 21 cases. J Clin Endocrinol Metab 2012;97:2093-104
   PubMed Web of Science ®Google Scholar